Lian Yu - Search Results

Year	Number of Results
2000	1
2001	1
2002	2
2003	5
2004	3
2005	11
2006	12
2007	13
2008	9
2009	8
2010	7
2011	13
2012	14
2013	13
2014	17
2015	19
2016	15
2017	28
2018	23
2019	32
2020	24
2021	24
2022	28
2023	42
2024	12

1

Single-cell transcriptomics dissects hematopoietic cell destruction and T-cell engagement in aplastic anemia.

Zhu C, Lian Y, Wang C, Wu P, Li X, Gao Y, Fan S, Ai L, Fang L, Pan H, Cheng T, Shi J, Zhu P. Zhu C, et al. Among authors: lian y. Blood. 2021 Jul 8;138(1):23-33. doi: 10.1182/blood.2020008966. Blood. 2021. PMID: 33763704 Free PMC article.

2

Role of tumor microenvironment in tumorigenesis.

Wang M, Zhao J, Zhang L, Wei F, Lian Y, Wu Y, Gong Z, Zhang S, Zhou J, Cao K, Li X, Xiong W, Li G, Zeng Z, Guo C. Wang M, et al. Among authors: lian y. J Cancer. 2017 Feb 25;8(5):761-773. doi: 10.7150/jca.17648. eCollection 2017. J Cancer. 2017. PMID: 28382138 Free PMC article. Review.

3

Polyamorphism of D-mannitol.

Zhu M, Yu L. Zhu M, et al. Among authors: yu l. J Chem Phys. 2017 Jun 28;146(24):244503. doi: 10.1063/1.4989961. J Chem Phys. 2017. PMID: 28668061

4

Amorphous Drug-Polymer Salts.

Yao X, Neusaenger AL, Yu L. Yao X, et al. Among authors: yu l. Pharmaceutics. 2021 Aug 17;13(8):1271. doi: 10.3390/pharmaceutics13081271. Pharmaceutics. 2021. PMID: 34452231 Free PMC article.

5

Mitochondrial tRNA pseudouridylation governs erythropoiesis.

Wang B, Shi D, Yang S, Lian Y, Li H, Cao M, He Y, Zhang L, Qiu C, Liu T, Wen W, Ma Y, Shi L, Cheng T, Shi L, Yuan W, Chu Y, Shi J. Wang B, et al. Among authors: lian y. Blood. 2024 Apr 18:blood.2023022004. doi: 10.1182/blood.2023022004. Online ahead of print. Blood. 2024. PMID: 38635773

6

Polymorphic selectivity in crystal nucleation.

Gui Y, Huang C, Shi C, Stelzer T, Zhang GGZ, Yu L. Gui Y, et al. Among authors: yu l. J Chem Phys. 2022 Apr 14;156(14):144504. doi: 10.1063/5.0086308. J Chem Phys. 2022. PMID: 35428390

7

Multi-target angiogenesis inhibitor combined with PD-1 inhibitors may benefit advanced non-small cell lung cancer patients in late line after failure of EGFR-TKI therapy.

Yu L, Hu Y, Xu J, Qiao R, Zhong H, Han B, Xia J, Zhong R. Yu L, et al. Int J Cancer. 2023 Aug 1;153(3):635-643. doi: 10.1002/ijc.34536. Epub 2023 Apr 20. Int J Cancer. 2023. PMID: 37078587

8

Linking long non-coding RNAs and SWI/SNF complexes to chromatin remodeling in cancer.

Tang Y, Wang J, Lian Y, Fan C, Zhang P, Wu Y, Li X, Xiong F, Li X, Li G, Xiong W, Zeng Z. Tang Y, et al. Among authors: lian y. Mol Cancer. 2017 Feb 17;16(1):42. doi: 10.1186/s12943-017-0612-0. Mol Cancer. 2017. PMID: 28212646 Free PMC article. Review.

9

Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.

Yu L, Xu J, Qiao R, Han B, Zhong H, Zhong R. Yu L, et al. Cancer Med. 2023 Mar;12(5):5372-5383. doi: 10.1002/cam4.5360. Epub 2022 Oct 17. Cancer Med. 2023. PMID: 36250532 Free PMC article. Review.

10

Research progress on the biological activities of selenium polysaccharides.

Zhou N, Long H, Wang C, Yu L, Zhao M, Liu X. Zhou N, et al. Among authors: yu l. Food Funct. 2020 Jun 24;11(6):4834-4852. doi: 10.1039/c9fo02026h. Food Funct. 2020. PMID: 32478773 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

341 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

341 results

Results by year